The tripping point : The potential role of psychedelic-assisted therapy in the response to the opioid crisis Elena Argento, Kenneth W. Tupper, M. Eugenia Socias International Journal of Drug Policy, 2019, 66, 80–81 https://doi.org/10.1016/j.drugpo.2018.11.006 0955-3959/ © 2018 Elsevier B.V. All rights reserved A B S T R A C T The increasing contamination of the drug supply with illicitly manufactured fentanyl and related analogs in North America has resulted in the most severe drug-overdose crisis in history. Available pharmaco-therapy options for the treatment of opioid use disorder have had limited success in curbing the current crisis, and a growing body of evidence highlights the need for [...]
Lire la suiteAssociation between medical cannabis laws and opioid overdose mortality has reversed over time Chelsea L. Shover, Corey S. Davis, Sanford C. Gordon, and Keith Humphreys PNAS, mai 2019 www.pnas.org/cgi/doi/10.1073/pnas.1903434116 Abstract Medical cannabis has been touted as a solution to the US opioid overdose crisis since Bachhuber et al. [M. A. Bachhuber, B. Saloner, C. O. Cunningham, C. L. Barry, JAMA Intern. Med. 174, 1668–1673] found that from 1999 to 2010 states with medical cannabis laws experienced slower increases in opioid analgesic overdose mortality. That research received substantial attention in the scientific literature and popular press and served as a talking point for the cannabis industry [...]
Lire la suiteMedical Cannabis No Solution to the Opioid Crisis Batya Swift Yasgur, MA, LSW Medscape Medical News, June 11, 2019 https://www.medscape.com/viewarticle/914256?nlid=130206_2052&src=WNL_mdplsnews_190614_mscpedit_psyc&uac=292598PZ&spon=12&impID=1994987&faf=1 Contrary to previous research and popular assumptions, legalization of, and broader access to, medical cannabis has not reduced opioid overdose death rates. A study at Stanford University in California showed no protective effect of medical cannabis. In fact, states that legalized medical cannabis actually experienced a 22.7% increase in opioid overdose deaths. "There has been an idea touted by people and the cannabis industry and everyone invested in finding solutions to the opioid crisis that passing cannabis laws is one way to do that," lead author [...]
Lire la suiteA Contemporary History of Ibogaine in the United States and Europe THE ALKALOIDS, 2001, Vol.56, Chapitre 14 Copyright © 2001 by Academic Press 0099-9598/01 Kenneth R. Alper, Dana Beal & Charles D. Kaplan I. Introduction In 1995, Dr. Curtis Wright, then the U.S. Food and Drug Administration (FDA) ibogaine project officer, wrote “What’s clear is that a significant portion of the public we serve believes the drug merits investigation” (1). Wright’s statement intimates a relationship of public opinion to regulatory scientific policy. The statement was made at a time when the FDA, partly in response to highly motivated and organized public advocacy, was modifying its drug [...]
Lire la suiteCannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder : A Double-Blind Randomized Placebo-Controlled Trial Yasmin L. Hurd, Ph.D., Sharron Spriggs, M.A., Julia Alishayev, R.P.A., Gary Winkel, Ph.D., Kristina Gurgov, R.P.A., Chris Kudrich, D.H.Sc., Anna M. Oprescu, M.P.H., Edwin Salsitz, M.D. AJP in Advance, 2019, 1-12. doi: 10.1176/appi.ajp.2019.18101191 Objective : Despite the staggering consequences of the opioid epidemic, limited nonopioid medication options have been developed to treat this medical and public health crisis. This study investigated the potential of cannabidiol (CBD), a nonintoxicating phytocannabinoid, to reduce cue-induced craving and anxiety, two critical features of addiction that often [...]
Lire la suite